
Anti-Malarial Drug Market Size Was Valued at USD 1034.24 Million in 2023 and is Projected to Reach USD 1563.66 Million by 2032, Growing at a CAGR of 4.7% From 2024-2032.
Antimalarial Drugs are a type of antiparasitic chemical agent, that are often naturally derived and can be used to treat or prevent malaria. Anti-malarial drugs are very much essential for the treatment of malaria. They help to kill the Plasmodium parasites which are responsible for the infection and alleviate the symptoms associated with the disease. Timely administration of these drugs can save lives and prevent severe complications.
They are also used for prevention purposes, particularly in regions where malaria is endemic, People living in or traveling to such areas may take prophylactic doses of these drugs to reduce the risk of contracting the disease. The drug-resistant strains of malaria parasites are a challenge in the fight against malaria hence, Anti-malarial drugs, including combination therapies, are designed to combat drug-resistant strains and prevent the further spread of resistance.The research and development of new anti-malarial drugs like Sulfadoxine-pyrimethamine and many others are also taking place to stay ahead of drug resistance and improve treatment options.
“Abbott Laboratories (USA), Astellas Pharma (Japan), AstraZeneca (UK), Bayer (Germany), Boehringer Ingelheim (Germany), Bristol Myers Squibb (USA), Cipla (India), Daiichi Sankyo (Japan), Dr. Reddy's Laboratories (India), Eisai Co., Ltd. (Japan), Gilead Sciences (USA), GlaxoSmithKline (GSK) (UK), Grifols (Spain), Johnson & Johnson (USA), Lupin Limited (India), Mallinckrodt Pharmaceuticals (USA), Merck & Co. (USA), Mylan (USA), Novartis (Switzerland), Pfizer (USA), Roche (Switzerland), Sanofi (France), Sun Pharmaceutical Industries (India), Guilin Pharmaceutical Co. Ltd (China), Teva Pharmaceutical Industries (Israel) and Other Active Players.”
Anti-Malarial Drug Market Segmented on the basis of Drug Class, Malaria Type, Mechanism of Action.
Anti-Malarial Drug Market |
|||
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 1034.24 Mn. |
Forecast Period 2024-32 CAGR: |
4.7 % |
Market Size in 2032: |
USD 1563.66 Mn. |
Segments Covered: |
By Drug Class |
|
|
By Malaria Type |
|
||
By Mechanism of Action |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Anti-Malarial Drug Market by By Drug Class
4.1 Anti-Malarial Drug Market Snapshot and Growth Engine
4.2 Anti-Malarial Drug Market Overview
4.3 Aryl amino alcohol compounds
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market
The forecast period in the Anti-Malarial Drug Market research report is 2024-2032.
Abbott Laboratories (USA), Astellas Pharma (Japan), AstraZeneca (UK), Bayer (Germany), Boehringer Ingelheim (Germany), Bristol Myers Squibb (USA), Cipla (India), Daiichi Sankyo (Japan), Dr. Reddy's Laboratories (India), Eisai Co., Ltd. (Japan), Gilead Sciences (USA), GlaxoSmithKline (GSK) (UK), Grifols (Spain), Johnson & Johnson (USA), Lupin Limited (India), Mallinckrodt Pharmaceuticals (USA), Merck & Co. (USA), Mylan (USA), Novartis (Switzerland), Pfizer (USA), Roche (Switzerland), Sanofi (France), Sun Pharmaceutical Industries (India), Guilin Pharmaceutical Co. Ltd (China), Teva Pharmaceutical Industries (Israel) and Other Active Players.
The Anti-Malarial Drug Market is segmented into Drug Class, Malaria Type, Mechanism of Action, and Region. By Drug Class, the market is categorized into Aryl amino alcohol compounds, Antifolate compounds, and Artemisinin compounds. By Malaria Type, the market is categorized into Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Malarie, and Plasmodium ovale. By Mechanism of Action, the market is categorized into Treatment for Malaria, Prevention from Malaria. By region, it is analyzed across North America (U.S.; Canada; Mexico), Eastern Europe (Bulgaria; The Czech Republic; Hungary; Poland; Romania; Rest of Eastern Europe), Western Europe (Germany; UK; France; Netherlands; Italy; Russia; Spain; Rest of Western Europe), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).
ANTI-MALARIAL DRUG Market Size Was Valued at USD 1034.24 Billion in 2023 and is Projected to Reach USD 1563.66 Billion by 2032, Growing at a CAGR of 4.7% From 2024-2032.
Antimalarial Drugs are a type of antiparasitic chemical agent, that are often naturally derived and can be used to treat or prevent malaria.